Content about Neurological disorders

January 3, 2012

Mothers that have low socioeconomic status and develop gestational diabetes during pregnancy are more likely to bear children that are diagnosed with attention deficit hyperactivity disorder, according to a new study published in the Archives of Pediatrics & Adolescent Medicine.

NEW YORK — Mothers that have low socioeconomic status and develop gestational diabetes during pregnancy are more likely to bear children that are diagnosed with attention deficit hyperactivity disorder, according to a new study published in the Archives of Pediatrics & Adolescent Medicine.

December 23, 2011

Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.

SAN FRANCISCO — Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.

December 15, 2011

A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.

SAM MATEO, Calif. — A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.

NeurogesX said Thursday that the FDA Anesthetic and Analgesic Drug Products Advisory Committee would meet on Feb. 9, 2012, to review the patch drug Qutenza (capsaicin) as a treatment for pain associated with HIV-associated peripheral neuropathy, or HIV-PN.

The drug currently is approved for treating pain associated with postherpetic neuralgia.

December 7, 2011

A drug in late-stage clinical trials appears to treat the symptoms of autism, the drug's developer said Wednesday.

RYE, N.Y. — A drug in late-stage clinical trials appears to treat the symptoms of autism, the drug's developer said Wednesday.

Curemark announced results of the phase-3 trial of CM-AT in children ages 3 to 8 years. The company said the drug had a statistically significant effect on symptoms of autism compared with placebo. The Food and Drug Administration has granted the drug fast-track status, which it does for investigational drugs to treat serious or life-threatening conditions that may address unmet medical needs.

November 14, 2011

A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

CAMBRIDGE, Mass. — A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

Genzyme, acquired earlier this year by French drug maker Sanofi, announced results of the phase-3 "CARE-MS II" trial of Lemtrada (alemtuzumab), saying the drug "significantly reduced" worsening of disability and relapse in patients with MS, compared with Rebif (interferon beta-1a), made by Pfizer and German drug maker Merck KGaA, a separate company from U.S.-based Merck.

October 31, 2011

A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.

TITUSVILLE, N.J. — A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.

October 24, 2011

The Food and Drug Administration has approved a new drug for treating a severe form of epilepsy, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a severe form of epilepsy, the agency said Monday.

The FDA announced the approval of Onfi (clobazam) tablets, made by Catalent Pharma Solutions and Lundbeck, as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in patients ages 2 years and older. The agency gave the drug orphan drug designation because the disease affects fewer than 200,000 people in the United States.

October 17, 2011

Children can be diagnosed with attention deficit hyperactivity disorder as soon as 4 years old, according to new guidelines released Sunday by the American Academy of Pediatrics.

BOSTON — Children can be diagnosed with attention deficit hyperactivity disorder as soon as 4 years old, according to new guidelines released Sunday by the American Academy of Pediatrics.

October 12, 2011

Multiple sclerosis patients treated with a drug made by Teva Pharmaceutical Industries showed a "significant" reduction in their loss of brain volume, according to a new study.

JERUSALEM — Multiple sclerosis patients treated with a drug made by Teva Pharmaceutical Industries showed a "significant" reduction in their loss of brain volume, according to a new study.

Results of a five-year study published in the Journal of the Neurological Sciences found that Copaxone (glatiramer acetate) produced significant reductions in patients' loss of brain volume compared with other disease-modifying therapies.

October 6, 2011

A drug under investigation by Sanofi for multiple sclerosis improved several measures of disease activity in patients, according to results of a late-stage clinical trial.

PARIS — A drug under investigation by Sanofi for multiple sclerosis improved several measures of disease activity in patients, according to results of a late-stage clinical trial.

September 28, 2011

Chelsea Therapeutics International has applied for Food and Drug Administration approval of a drug for a disorder that affects patients with diseases like Parkinson's disease.

CHARLOTTE, N.C. — Chelsea Therapeutics International has applied for Food and Drug Administration approval of a drug for a disorder that affects patients with diseases like Parkinson's disease.

The drug maker announced the submission of a new drug application for Northera (droxidopa) as a treatment for neurogenic orthostatic hypotension. NOH predominantly affects people with primary autonomic failure, a group of diseases that includes Parkinson's, multiple system atrophy and pure autonomic failure.

August 30, 2011

A drug under late-stage clinical development by Eisai reduced the frequency of seizures in patients with epilepsy, according to trial results the drug maker presented Tuesday at the 2011 International Epilepsy Congress.

WOODCLIFF LAKE, N.J. — A drug under late-stage clinical development by Eisai reduced the frequency of seizures in patients with epilepsy, according to trial results the drug maker presented Tuesday at the 2011 International Epilepsy Congress.

August 19, 2011

Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.

SCHAUMBURG, Ill. — Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.

Sagent announced the launch of vecuronium bromide, an injectable drug used to treat myasthenia gravis and Eaton-Lambert syndrome. The disorders cause muscle weakness and fatigue.

The market for vecuronium bromide is about $10 million in the United States, according to IMS Health.

August 17, 2011

Mylan announced Wednesday that it filed with the Food and Drug Administration for approval of a generic version of a drug for migraine headaches made by Endo Pharmaceuticals.

PITTSBURGH — Mylan announced Wednesday that it filed with the Food and Drug Administration for approval of a generic version of a drug for migraine headaches made by Endo Pharmaceuticals.

Mylan said it was the first to file for approval of a generic version of Frova (frovatriptan succinate EQ) tablets in the 2.5-mg strength. In response, Endo has filed a patent infringement lawsuit against Mylan in response to the filing.

Frova had sales of $68.2 million during the 12-month period ended in June, according to IMS Health.

August 2, 2011

The Food and Drug Administration has approved a new use for a drug made by Novartis for treating multiple sclerosis, the Swiss drug maker's U.S. subsidiary said Monday.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a new use for a drug made by Novartis for treating multiple sclerosis, the Swiss drug maker's U.S. subsidiary said Monday.

Novartis Pharmaceuticals announced the FDA's approval of Gilenya (fingolimod) for the reduction of T1 gadolinium-enhancing lesions, areas of inflammation in the central nervous system that mark disease activity in people with MS.

July 18, 2011

Upsher-Smith Labs has started a late-stage clinical trial of a drug for treating patients with a rare and severe form of epilepsy, the drug maker said Monday.

MAPLE GROVE, Minn. — Upsher-Smith Labs has started a late-stage clinical trial of a drug for treating patients with a rare and severe form of epilepsy, the drug maker said Monday.

July 12, 2011

PuraMed BioScience on Monday announced that headache researcher Roger Cady will be exhibiting a poster presentation of his independent clinical study of PuraMed's nonprescription migraine medication LipiGesic-M at the 2011 Headache Update Conference being held in Orlando, Fla., July 14 to 17.

SCHOFIELD, Wis. — PuraMed BioScience on Monday announced that headache researcher Roger Cady will be exhibiting a poster presentation of his independent clinical study of PuraMed's nonprescription migraine medication LipiGesic-M at the 2011 Headache Update Conference being held in Orlando, Fla., July 14 to 17.

June 17, 2011

Nipro Diagnostics and NeuroMetrix have teamed up to market a point-of-care test that is designed to evaluate such systemic neuropathies as diabetic peripheral neuropathy.

WALTHAM, Mass. — Nipro Diagnostics and NeuroMetrix have teamed up to market a point-of-care test that is designed to evaluate such systemic neuropathies as diabetic peripheral neuropathy.

Nipro and NeuroMetrix said the NC-stat DPNCheck test, developed by NeuroMetrix, could offer a cost-effective approach to detecting and monitoring DPN, which affects more than half of people with diabetes and could lead to such conditions as foot ulcers and limb amputation.

The companies currently are evaluating opportunities for the NC-stat DPNCheck in retail medical clinics.

April 12, 2011

An investigational drug made by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis reduced disease relapses and prevented the progression of disability, according to late-stage clinical trial results announced Monday.

JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis reduced disease relapses and prevented the progression of disability, according to late-stage clinical trial results announced Monday.

April 11, 2011

A drug originally developed by scientists in the Soviet Union to treat allergies and currently under investigation by Pfizer and Medivation did not yield significant results in a late-stage clinical trial of patients with Huntington disease, a disorder that leads to cognitive decline, the companies said Monday.

NEW YORK — A drug originally developed by scientists in the Soviet Union to treat allergies and currently under investigation by Pfizer and Medivation did not yield significant results in a late-stage clinical trial of patients with Huntington disease, a disorder that leads to cognitive decline, the companies said Monday.

March 8, 2011

GREENSBORO, N.C. — Merz Pharmaceuticals has created two programs to provide financial assistance to patients using its drug for cervical dystonia, the company said Tuesday.

The programs — the Xeomin patient co-payment program and the Xeomin patient assistance program — cover Xeomin (incobotulinumtoxinA), designed to decrease the severity of abnormal head positions and neck pains in patients with the disease, which causes muscle contractions resulting in repetitive movements and abnormal postures.

March 4, 2011

The Food and Drug Administration has approved a drug made by Eisai to treat a rare form of epilepsy, the drug maker said Friday.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a drug made by Eisai to treat a rare form of epilepsy, the drug maker said Friday.

The FDA approved Banzel (rufinamide) oral suspension for the treatment of seizures in children and adults with Lennox-Gastaut syndrome. The condition, also called LGS, affects 1% to 4% of children with epilepsy.

“This new formulation provides an option for patients who may prefer a liquid or find it difficult to take the medication in tablet form,” Eisai president and CEO Lonnel Coats said.

March 3, 2011

The Food and Drug Administration declined to approve a Merck KGaA drug designed to treat relapsing-remitting multiple sclerosis.

DARMSTADT, Germany — The Food and Drug Administration declined to approve a Merck KGaA drug designed to treat relapsing-remitting multiple sclerosis.

February 22, 2011

Generic drug maker Hi-Tech Pharmacal has received Food and Drug Administration approval for its version of a drug used to treat neurological disorders, the company said Tuesday.

AMITYVILLE, N.Y. — Generic drug maker Hi-Tech Pharmacal has received Food and Drug Administration approval for its version of a drug used to treat neurological disorders, the company said Tuesday.

Hi-Tech announced the approval of gabapentin oral solution in the 250 mg/5 mL strength, a generic version of Pfizer’s Neurontin oral solution.

The drug is used to treat postherpetic neuralgia and epilepsy. Neurontin had sales of $15 million in 2010, according to IMS Health.

February 3, 2011

US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

LOUISVILLE, Ky. — US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

The company announced the launch of Alsuma auto-injector (sumatriptan), which injects the drug sumatriptan under the skin via a single-use, prefilled auto injector. The company is selling the drug under a licensing agreement from King Pharmaceuticals.